|
Document and Entity Information
|
6 Months Ended |
|---|---|
|
Jun. 30, 2013
|
|
| Document Information [Line Items] | |
| Document Type | 6-K |
| Amendment Flag | false |
| Document Period End Date | Jun. 30, 2013 |
| Document Fiscal Year Focus | 2013 |
| Document Fiscal Period Focus | Q2 |
| Trading Symbol | ICLR |
| Entity Registrant Name | ICON PLC /ADR/ |
| Entity Central Index Key | 0001060955 |
| Current Fiscal Year End Date | --12-31 |
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Noncurrent capital government grants, which are amortized and recognized in earnings over the grant period. No definition available.
|
| X | ||||||||||
|
- Definition
Capital Redemption Reserve No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Condensed Consolidated Balance Sheets (Parenthetical) (EUR €)
|
Jun. 30, 2013
|
Dec. 31, 2012
|
|---|---|---|
| Ordinary shares, par value | € 0.06 | € 0.06 |
| Ordinary shares, shares authorized | 100,000,000 | 100,000,000 |
| Ordinary shares, shares issued | 60,861,741 | 60,287,498 |
| Ordinary shares, shares outstanding | 60,861,741 | 60,287,498 |
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Condensed Consolidated Statements of Operations (USD $)
In Thousands, except Share data, unless otherwise specified |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
|
| Revenue: | ||||
| Gross revenue | $ 469,626 | $ 379,620 | $ 888,685 | $ 722,675 |
| Reimbursable expenses | (135,407) | (102,613) | (237,677) | (193,335) |
| Net revenue | 334,219 | 277,007 | 651,008 | 529,340 |
| Costs and expenses: | ||||
| Direct costs | 214,231 | 180,127 | 416,592 | 342,411 |
| Selling, general and administrative expense | 77,548 | 69,410 | 153,112 | 136,925 |
| Depreciation and amortization | 11,520 | 10,830 | 22,976 | 21,632 |
| Restructuring and other items | 4,621 | 5,636 | 9,033 | 5,636 |
| Total costs and expenses | 307,920 | 266,003 | 601,713 | 506,604 |
| Income from operations | 26,299 | 11,004 | 49,295 | 22,736 |
| Interest income | 274 | 314 | 455 | 693 |
| Interest expense | (374) | (545) | (740) | (959) |
| Income before provision for income taxes | 26,199 | 10,773 | 49,010 | 22,470 |
| Provision for income taxes | (3,720) | (2,809) | (7,486) | (5,535) |
| Net income | $ 22,479 | $ 7,964 | $ 41,524 | $ 16,935 |
| Net income per Ordinary Share: | ||||
| Basic | $ 0.37 | $ 0.13 | $ 0.69 | $ 0.28 |
| Diluted | $ 0.36 | $ 0.13 | $ 0.67 | $ 0.28 |
| Weighted average number of Ordinary Shares outstanding: | ||||
| Basic | 60,724,296 | 59,978,509 | 60,555,945 | 60,032,306 |
| Diluted | 61,898,903 | 60,630,891 | 61,607,757 | 60,607,635 |
| X | ||||||||||
|
- Definition
Amount charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding asset retirement obligations net of research and development incentives. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Increase (Decrease) In Prepaid Expense And Other Current Assets No definition available.
|
| X | ||||||||||
|
- Definition
Payments for Share Repurchase Costs No definition available.
|
| X | ||||||||||
|
- Definition
Amortization of Government Grants. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Condensed Consolidated Statements of Shareholders' Equity and Comprehensive Income (USD $)
In Thousands, except Share data, unless otherwise specified |
Total
|
Ordinary Shares
|
Additional Paid-in Capital
|
Capital Redemption Reserve
|
Accumulated Other Comprehensive Income
|
Retained Earnings
|
|---|---|---|---|---|---|---|
| Balance at Dec. 31, 2012 | $ 754,575 | $ 5,067 | $ 237,217 | $ 100 | $ (8,776) | $ 520,967 |
| Balance (in shares) at Dec. 31, 2012 | 60,287,498 | |||||
| Comprehensive Income: | ||||||
| Net income | 41,524 | 41,524 | ||||
| Currency translation adjustment | (5,935) | (5,935) | ||||
| Currency impact of long term funding | (4,172) | (4,172) | ||||
| Tax on currency impact of long term funding | (227) | (227) | ||||
| Unrealized capital gain - investments | (205) | (205) | ||||
| Total comprehensive income | 30,985 | (10,539) | 41,524 | |||
| Exercise of share options (in shares) | 524,243 | |||||
| Exercise of share options | 10,544 | 42 | 10,502 | |||
| Issue of restricted share units (in shares) | 50,000 | |||||
| Issue of restricted share units | 4 | 4 | ||||
| Share issuance costs | (59) | (59) | ||||
| Non-cash stock compensation expense | 5,466 | 5,466 | ||||
| Tax benefit on exercise of options | 193 | 193 | ||||
| Balance at Jun. 30, 2013 | $ 801,708 | $ 5,109 | $ 253,323 | $ 100 | $ (19,315) | $ 562,491 |
| Balance (in shares) at Jun. 30, 2013 | 60,861,741 |
| X | ||||||||||
|
- Definition
Adjustment that results from the process of translating the impact of long-term funding into the functional currency of the reporting entity. No definition available.
|
| X | ||||||||||
|
- Definition
Tax impact on the adjustment that results from the process of translating the impact of long-term funding into the functional currency of the reporting entity. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Basis Of Presentation
|
6 Months Ended |
|---|---|
|
Jun. 30, 2013
|
|
| Basis Of Presentation |
1. Basis of Presentation
These
condensed consolidated financial statements, which have been
prepared in accordance with United States generally accepted
accounting principles (“US GAAP”), have not been
audited. The condensed consolidated financial statements reflect
all adjustments, which are, in the opinion of management, necessary
to present a fair statement of the operating results and financial
position for the periods presented. The preparation of the
condensed consolidated financial statements in conformity with US
GAAP requires management to make estimates and assumptions that
affect reported amounts and disclosures in the condensed
consolidated financial statements. Actual results could differ from
those estimates.
The
condensed consolidated financial statements should be read in
conjunction with the accounting policies and notes to the
consolidated financial statements included in ICON’s Form
20-F for the year ended December 31, 2012. Operating results for
the six months ended June 30, 2013 are not necessarily indicative
of the results that may be expected for the fiscal period ending
December 31, 2013.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Goodwill
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Goodwill |
2. Goodwill
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Business Combinations
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Combinations |
3. Business Combinations
Acquisition - Clinical Trial Services Division of Cross Country
Healthcare, Inc.
On
February 15, 2013 the Company acquired the clinical trial services
division of Cross Country Healthcare Inc. for an initial cash
consideration of $51.9 million. The agreement provided for further
consideration of up to $3.75 million which may become payable if
certain performance milestones are achieved during the period ended
December 31, 2013. Cross Country Healthcare’s
Clinical Trial Services division includes US resourcing providers,
ClinForce and Assent Consulting, whose services include contract
staffing, permanent placement and functional service provision. The
division also includes AKOS, a leading US and EU provider of
pharmacovigilance and drug safety services. ClinForce and Assent
will be combined with ICON’s FSP division, DOCS, creating a
leader in global resourcing and FSP, while AKOS will enhance the
services offered by ICON’s medical and safety services team.
Certain operating margin perfomance milestones in relation to
ClinForce and Assent Consulting were not achieved during the period
ended March 31, 2013 resulting in a reduction of $1.5 million to
the contingent consideration. At June 30, 2013 the Company has
recorded a liability of $2.25 million in respect of the additional
consideration. At June 30, 2013 $2.25 million was held
in escrow in relation to additional amounts potentially payable
under the acquisition, and this is presented as resticted cash on
the condensed consolidated balance sheet.
The
acquisition of the clinical trial services division of Cross
Country Healthcare, Inc has been accounted for as a business
combination in accordance with FASB ASC 805 Business Combinations.
The following table summarizes the preliminary estimated fair
values of the assets acquired and the liabilities
assumed:
*
Goodwill represents the acquisition of an established workforce
with experience in the clinical research industry, thereby allowing
the Company to enhance its capabilities in global resourcing and
FSP and also medical and safety services. Goodwill related to the
US portion of the business acquired is tax deductible.
Prior Period Acquisitions - Acquisition of
PriceSpective
On
February 28, 2012 the Company acquired 100% of the common stock of
PriceSpective LLC (PriceSpective) strategy consulting company for
an initial cash consideration of $37.1
million. Headquartered in Philadelphia, and with offices
in London, Los Angeles, San Diego, Raleigh and Boston,
PriceSpective is a premier consultancy that has a strong reputation
for excellence in strategic pricing, market access, Health
Economics and Outcomes Research (“HEOR”), due diligence
support and payer engagement services. Since PriceSpective’s
incorporation in 2003, it has developed strategies for dozens of
new product launches, and hundreds of development and in-market
products, across 40+ disease areas. Further consideration of up to
$15.0 million was payable if certain performance milestones were
achieved in respect of periods up to December 31, 2012. On August
13, 2012 the Company paid $5.0 million in relation to performance
milestones for the year ended December 31, 2011. On May 29, 2013
the Company paid $10.0 million in relation to the remaining
performance milestones for the year ended December 31,
2012.
The
acquisition of PriceSpective has been accounted for as a business
combination in accordance with FASB ASC 805 Business Combinations.
The following table summarizes the estimated fair values of the
assets acquired and the liabilities assumed:
*
Goodwill represents the acquisition of an established workforce
with experience in strategic pricing, market access, HEOR, due
diligence support and payer engagement services. Goodwill related
to the US portion of the business acquired is tax
deductible.
Prior Period Acquisitions - Acquisition of BeijingWits
Medical
On
February 15, 2012 the Company acquired 100% of the common stock of
BeijingWits Medical Consulting Co. Limited (BeijingWits Medical), a
leading Chinese CRO, for an initial cash consideration of $9.0
million. BeijingWits Medical offers full-service clinical
development capabilities and has a strong track record in clinical
trial execution in China. It is a renowned expert in Chinese
regulatory processes and a leading advocate of International
Conference on Harmonisation Good Clinical Practice (“ICH
GCP”) in China. In addition to boosting the Company’s
service capabilities in the region, BeijingWits Medical will also
strengthen the Company’s presence through the addition of
over 100 highly qualified and experienced professionals in Beijing,
Shanghai, Chengdu, Guangzhou, Wuhan and Hong Kong. Further
consideration of up to $7.0 million may become payable if certain
performance milestones are achieved in respect of periods up to
December 31, 2013. On June 13, 2013 the Company paid $3.8 million
in relation to the remaining performance milestones for the year
ended December 31, 2012. At June 30, 2013 the Company has recorded
a liability of $3.2 million in respect of the additional
consideration.
The
acquisition of BeijingWits has been accounted for as a business
combination in accordance with FASB ASC 805 Business Combinations.
The following table summarizes the estimated fair values of the
assets acquired and the liabilities assumed:
*
Goodwill represents the acquisition of an established workforce
with experience in clinical trial execution and regulatory
processes in China and is not tax deductible.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Restructuring and Other Items
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Restructuring and Other Items |
4. Restructuring and other items
Restructuring
and other items recognized comprise:
Restructuring Charges
Restructuring
charges of $4.4 million were recognized during three months ended
March 31, 2013 under a restructuring plan adopted following a
review by the Company of its operations. Under this restructuring
plan the Company announced the closure of its Phase I facility in
Omaha, Nebraska. This followed the expansion of the Company’s
Phase I facility in San Antonio, Texas and the consolidation of the
Company’s US Phase I capabilities in this location. The
restructuring plan also included resource rationalizations in
certain areas of the business to improve resource utilization. The
restructuring charge recognized included $0.5 million in respect of
lease termination costs associated with the Omaha facility and $3.9
million in respect of resource rationalizations. During the three
months ended June 30, 2013 the Company implemented a further
restructuring plan which contains Company resource rationalizations
in order to improve operating efficiencies and reduce expenses. A
restructuring charge of $4.6 million was recognized during the
three months ended June 30, 2013, $0.4 million in respect of lease
termination and asset write-down costs and $4.2 million in respect
of resource rationalizations.
Details
of the movement in this restructuring plan recognized are as
follows:
Prior Period Restructuring Charges
Restructuring
charges of $4.5 million were recorded during year ended December
31, 2012 (inclusive of the release of $0.1 million relating to the
2011 Restructuring Plans) under a restructuring plan (“the
2012 restructuring plan”) adopted following a review by the
Company of its operations. The 2012 restructuring plan included
resource rationalizations in certain areas of the business and a
re-organization of available office space at the Company’s
Philadelphia facility. The restructuring plan recognized included
$3.4 million in respect of resource rationalizations and $1.2
million in respect of lease termination and exit costs associated
with the re-organization of available space at the Company’s
Philadelphia facility.
Details
of the movement in the 2012 restructuring plan are as
follows:
Other Charges
On
September 30, 2011 Mr. Peter Gray, Vice-Chairman of the Board,
retired as Chief Executive Officer (“CEO”) of the
Company, in accordance with the provisions of his service
agreement, which was terminable on twelve months notice by either
party. On June 11, 2012 the Company entered into an
agreement with Mr. Gray whereby Mr. Gray’s employment and
directorship of ICON plc and other ICON group companies would
terminate on July 19, 2012. Under the terms of this
agreement Mr. Gray would be entitled to be paid €160,000
($200,000) in lieu of the balance of his notice period and to
receive a discretionary bonus of €194,000 ($243,000) in
respect of 2012. In addition, under the agreement Mr.
Gray’s unvested share options would vest on the date of
termination of his employment. The Company recognised a
share-based compensation charge of $620,000 in respect of these
options during the three months ended June 30, 2012.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Income Taxes
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income Taxes |
5. Income Taxes
Income
taxes recognized during the three and six months ended June 30,
2013 comprise:
As
at June 30, 2013 the Company maintains a $9.5 million liability
(December 31, 2012: $8.3 million) for unrecognized tax benefit,
which is comprised of $8.1 million (December 31, 2012: $7.2
million) related to items generating unrecognized tax benefits and
$1.4 million (December 31, 2012: $1.1 million) for interest and
related penalties to such items. The Company recognizes interest
accrued on unrecognized tax benefits as an additional income tax
expense.
The
Company has analyzed filing positions in all of the significant
federal, state and foreign jurisdictions where it is required to
file income tax returns, as well as open tax years in these
jurisdictions. The only periods subject to examination by the major
tax jurisdictions where the Company does business are 2008 through
2012 tax years. The Company does not believe that the outcome of
any examination will have a material impact on its financial
statements.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Net income Per Ordinary Share
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net income Per Ordinary Share |
6. Net income per ordinary share
Basic
net income per ordinary share has been computed by dividing net
income available to ordinary shareholders by the weighted average
number of ordinary shares outstanding during the period. Diluted
net income per ordinary share is computed by adjusting the weighted
average number of ordinary shares outstanding during the period for
all potentially dilutive ordinary shares outstanding during the
period and adjusting net income for any changes in income or loss
that would result from the conversion of such potential ordinary
shares. There is no difference in net income used for basic and
diluted net income per ordinary share.
The
reconciliation of the number of shares used in the computation of
basic and diluted net income per ordinary share is as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Share-based Awards
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based Awards |
7. Share-based Awards
Share Options
On
July 21, 2008 the Company adopted the Employee Share Option Plan
2008 (the “2008 Employee Plan”) pursuant to which the
Compensation and Organization Committee of the Company’s
Board of Directors may grant options to any employee, or any
director holding a salaried office or employment with the Company
or a Subsidiary for the purchase of ordinary shares. On the same
date, the Company also adopted the Consultants Share Option Plan
2008 (the “2008 Consultants Plan”), pursuant to which
the Compensation and Organization Committee of the Company’s
Board of Directors may grant options to any consultant, adviser or
non-executive director retained by the Company or any Subsidiary
for the purchase of ordinary shares.
Each
option granted under the 2008 Employee Plan or the 2008 Consultants
Plan (together the “2008 Option Plans”) will be an
employee stock option, or NSO, as described in Section 422 or 423
of the Internal Revenue Code. Each grant of an option under the
2008 Options Plans will be evidenced by a Stock Option Agreement
between the optionee and the Company. The exercise price will be
specified in each Stock Option Agreement, however option prices
will not be less than 100% of the fair market value of an ordinary
share on the date the option is granted.
An
aggregate of 6.0 million ordinary shares have been reserved under
the 2008 Employee Plan, as reduced by any shares issued or to be
issued pursuant to options granted under the 2008 Consultants Plan,
under which a limit of 400,000 shares applies. Further,
the maximum number of ordinary shares with respect to which options
may be granted under the 2008 Employee Option Plan, during any
calendar year to any employee shall be 400,000 ordinary
shares. There is no individual limit under the 2008
Consultants Plan. No options may be granted under
the 2008 Option Plans after July 21, 2018.
On
January 17, 2003 the Company adopted the Share Option Plan 2003
(the “2003 Share Option Plan”) pursuant to which the
Compensation and Organization Committee of the Board could grant
options to officers and other employees of the Company or its
subsidiaries for the purchase of ordinary shares. An
aggregate of 6.0 million ordinary shares were reserved under the
2003 Share Option Plan; and, in no event could the number of
ordinary shares issued pursuant to options awarded under
this plan exceed 10% of the outstanding shares, as defined in the
2003 Share Option Plan, at the time of the grant, unless the Board
expressly determined otherwise. Further, the maximum number of
ordinary shares with respect to which options could be granted
under the 2003 Share Option Plan during any calendar year to any
employee was 400,000 ordinary shares. The 2003 Share
Option Plan expired on January 17, 2013. No new options
may be granted under this plan.
Share
option awards are granted with an exercise price equal to the
market price of the Company’s shares at date of
grant. Share options typically vest over a period of
five years from date of grant and expire eight years from date of
grant. The maximum contractual term of options
outstanding at June 30, 2013 is eight years.
The
following table summarizes option activity for the six months ended
June 30, 2013:
The
Company has granted options with fair values ranging from $3.68 to
$13.93 per option or a weighted average fair value of $8.81 per
option. The Company issues ordinary shares for all options
exercised. The total amount of fully vested share options which
remained outstanding at June 30, 2013, was 2,203,758. Fully vested
share options at June 30, 2013 have an average remaining
contractual term of 3.32 years, an average exercise price of $24.40
and a total intrinsic value of $24.3 million. The total intrinsic
value of options exercised during the six months ended June 30,
2013, was $7.8 million (June 30, 2012: $3.2 million).
The
following table summarizes the movement in non-vested share options
for the six months ended June 30, 2013:
Fair value of Stock Options Assumptions
The
weighted average fair value of options granted during the periods
ended June 30, 2013 and June 30, 2012 was calculated using the
Black-Scholes option pricing model. The weighted average
fair values and assumptions used were as follows:
Expected
volatility is based on the historical volatility of our common
stock over a period equal to the expected term of the options; the
expected life represents the weighted average period of time that
options granted are expected to be outstanding given consideration
to vesting schedules and our historical experience of past vesting
and termination patterns. The risk-free rate is based on the U.S.
government zero-coupon bonds yield curve in effect at time of the
grant for periods corresponding with the expected life of the
option.
Restricted Share Units and Performance Share Units
On
July 21, 2008 the Company adopted the 2008 Employees Restricted
Share Unit Plan (the “2008 RSU Plan”) pursuant to which
the Compensation and Organization Committee of the Company’s
Board of Directors may select any employee, or any director holding
a salaried office or employment with the Company, or a Subsidiary
to receive an award under the plan. An aggregate of 1.0
million ordinary shares have been reserved for issuance under the
2008 RSU Plan.
On
April 23, 2013 the Company adopted the 2013 Employees Restricted
Share Unit and Performance Share Unit Plan (the “2013 RSU and
PSU Plan”) pursuant to which the Compensation and
Organization Committee of the Company’s Board of Directors
may select any employee, or any director holding a salaried office
or employment with the Company, or a Subsidiary to receive an award
under the plan. An aggregate of 1.6 million ordinary
shares have been reserved for issuance under the 2013 RSU and PSU
Plan.
The
Company has awarded RSU’s and PSU’s to certain key
individuals of the Group. The following table summarizes RSU
activity for the six months ended June 30, 2013:
The
fair value of RSU’s vested for the six months ended June 30,
2013 totaled $1.1 million (No RSU’s vested during
2012).
The
PSU’s vest based on service and specified EPS targets. The
maximum number of PSU’s that could vest is 369,020 based on
attaining cumulative EPS targets over the period 2013 –
2015.
Non-cash stock compensation expense
Non-cash
stock compensation expense for the three and six months ended June
30, 2013 has been allocated as follows:
Total
non-cash stock compensation expense not yet recognized at June 30,
2013 amounted to $43.0 million. The weighted average
period over which this is expected to be recognized is 2.9
years. Total tax benefit recognized in additional paid
in capital related to the non-cash compensation expense amounted to
$0.2 million for the six months ended June 30, 2013 (June 30, 2012:
$0.9 million).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Share-based Compensation Arrangements by Share-based Payment Award. No definition available.
|
|
Business Segment Information
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Segment Information |
8. Business Segment Information
The
Company determines and presents operating segments based on the
information that is internally provided to the Chief Executive
Officer and Chief Financial Officer, who together are considered
the Company’s chief operating decision maker, in accordance
with FASB ASC 280-10 Disclosures about Segments of
an Enterprise and Related Information.
The
Company is a contract research organization (“CRO”),
providing outsourced development services on a global basis to the
pharmaceutical, biotechnology and medical device industries. It
specializes in the strategic development, management and analysis
of programs that support all stages of the clinical development
process - from compound selection to Phase I-IV clinical
studies. The Company earns revenues by providing a
number of different services to its customers. These services,
which are integral elements of the clinical development process,
include clinical trials management, biometric activities,
consulting, imaging, contract staffing, informatics and laboratory
services. The Company has the expertise and capability to conduct
clinical trials in most major therapeutic areas on a global basis
and has the operational flexibility to provide development services
on a stand-alone basis or as part of an integrated “full
service” solution. The Company has expanded
predominately through organic growth, together with a number of
strategic acquisitions to enhance its expertise and capabilities in
certain areas of the clinical development process.
Historically,
the Group organized, operated and assessed its business in two
segments, the clinical research segment and the central laboratory
segment. In 2013 the Group have consolidated and
reclassified the results of the former central laboratory segment
into the clinical research segment as the central laboratory
segment does not reach the thresholds of net revenue, income from
operations and total assets as a requirement for being reported as
a separate segment. Management have determined that its
clinical research and central laboratory businesses operate in the
same clinical research market, have a similar customer profile, are
subject to the same regulatory environment, support the development
of new clinical therapies and are so economically similar,
reporting their results on an aggregated basis would be more useful
to users of the Company’s financial statements.
The
Company's areas of operation outside of Ireland include the United
States, United Kingdom, France, Germany, Italy, Spain, The
Netherlands, Sweden, Belgium, Poland, Czech Republic, Lithuania,
Latvia, Russia, Ukraine, Hungary, Israel, Romania, Canada, Mexico,
Brazil, Colombia, Argentina, Chile, Peru, India, China, South
Korea, Japan, Thailand, Taiwan, Singapore, The Philippines,
Australia, New Zealand, and South Africa.
Segment
information as at June 30, 2013 and December 31, 2012 and for the
three and six months ended June 30, 2013 and June 30, 2012 is as
follows:
a)
The distribution of net revenue by geographical area was as
follows:
*
All sales shown for Ireland are export sales.
b)
The distribution of income from operations, including restructuring
and other items, by geographical area was as follows:
c)
The distribution of income from operations, excluding restructuring
and other items, by geographical area was as follows:
d)
The distribution of property, plant and equipment, net, by
geographical area was as follows:
e)
The distribution of depreciation and amortization by geographical
area was as follows:
f)
The distribution of total assets by geographical area was as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Goodwill (Tables)
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Goodwill |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Business Combinations (Tables)
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Clinical Trial Services
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Estimates of Fair Values of Assets Acquired and Liabilities Assumed | The
following table summarizes the preliminary estimated fair values of
the assets acquired and the liabilities assumed:
*
Goodwill represents the acquisition of an established workforce
with experience in the clinical research industry, thereby allowing
the Company to enhance its capabilities in global resourcing and
FSP and also medical and safety services. Goodwill related to the
US portion of the business acquired is tax deductible.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
PriceSpective LLC
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Estimates of Fair Values of Assets Acquired and Liabilities Assumed | The
following table summarizes the estimated fair values of the assets
acquired and the liabilities assumed:
*
Goodwill represents the acquisition of an established workforce
with experience in strategic pricing, market access, HEOR, due
diligence support and payer engagement services. Goodwill related
to the US portion of the business acquired is tax
deductible.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
BeijingWits Medical Limited
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Estimates of Fair Values of Assets Acquired and Liabilities Assumed | The
following table summarizes the estimated fair values of the assets
acquired and the liabilities assumed:
*
Goodwill represents the acquisition of an established workforce
with experience in clinical trial execution and regulatory
processes in China and is not tax deductible.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Preliminary Fair Values of Assets Acquired and Liabilities Assumed Related to Acquisition. No definition available.
|
|
Restructuring and Other Items (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recognized Restructuring and Other Items | Restructuring
and other items recognized comprise:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Details of Movement in Restructuring Provisions Recognized | Details
of the movement in this restructuring plan recognized are as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Prior Period Restructuring Charges | Details
of the movement in the 2012 restructuring plan are as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Restructuring Charges. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Income Taxes (Tables)
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income Tax Expense (Benefit) | Income
taxes recognized during the three and six months ended June 30,
2013 comprise:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Net income Per Ordinary Share (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reconciliation of Number of Shares Used in Computation of Basic and Diluted Net Income Per Ordinary Share | The
reconciliation of the number of shares used in the computation of
basic and diluted net income per ordinary share is as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Share-based Awards (Tables)
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Stock Option Activity | The
following table summarizes option activity for the six months ended
June 30, 2013:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Movement in Non-Vested Share Options | The
following table summarizes the movement in non-vested share options
for the six months ended June 30, 2013:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Weighted Average Fair Values and Assumptions Used | The
weighted average fair value of options granted during the periods
ended June 30, 2013 and June 30, 2012 was calculated using the
Black-Scholes option pricing model. The weighted average
fair values and assumptions used were as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of RSU Activity | The
following table summarizes RSU activity for the six months ended
June 30, 2013:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Non-Cash Stock Compensation Expense | Non-cash
stock compensation expense for the three and six months ended June
30, 2013 has been allocated as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Schedule of Non Cash Stock Compensation Expense. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Business Segment Information (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Net Revenue by Geographical Area | a)
The distribution of net revenue by geographical area was as
follows:
*
All sales shown for Ireland are export sales.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Income from Operations by Geographical Area | b)
The distribution of income from operations, including restructuring
and other items, by geographical area was as follows:
c)
The distribution of income from operations, excluding restructuring
and other items, by geographical area was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Property, Plant and Equipment, Net, by Geographical Area | d)
The distribution of property, plant and equipment, net, by
geographical area was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Depreciation and Amortization by Geographical Area | e)
The distribution of depreciation and amortization by geographical
area was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Total Assets by Geographical Area | f)
The distribution of total assets by geographical area was as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Operating Income by Geography. No definition available.
|
| X | ||||||||||
|
- Definition
Property, Plant and Equipment by Geography. No definition available.
|
| X | ||||||||||
|
- Definition
Schedule Of Depreciation And Amortization Expense By Geographical Area. No definition available.
|
| X | ||||||||||
|
- Definition
Schedule Of Total Assets By Geographic Area. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Goodwill (Detail) (USD $)
In Thousands, unless otherwise specified |
6 Months Ended | 12 Months Ended |
|---|---|---|
|
Jun. 30, 2013
|
Dec. 31, 2012
|
|
| Goodwill [Line Items] | ||
| Opening balance | $ 315,441 | $ 253,393 |
| Current period acquisitions | 43,877 | 55,759 |
| Prior period acquisitions | 1,382 | |
| Foreign exchange movement | (4,739) | 4,907 |
| Closing balance | $ 354,579 | $ 315,441 |
| X | ||||||||||
|
- Definition
Goodwill Acquired Prior Period No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Business Combinations - Additional Information (Detail) (USD $)
|
6 Months Ended | 1 Months Ended | 3 Months Ended | 1 Months Ended | 1 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Feb. 15, 2013
Clinical Trial Services
|
Mar. 31, 2013
Clinical Trial Services
|
Jun. 30, 2013
Clinical Trial Services
|
Feb. 15, 2013
Clinical Trial Services
Maximum
|
Aug. 13, 2012
PriceSpective LLC
|
Feb. 28, 2012
PriceSpective LLC
|
May 29, 2013
PriceSpective LLC
|
Feb. 28, 2012
PriceSpective LLC
Maximum
|
Jun. 13, 2013
BeijingWits Medical Limited
|
Feb. 15, 2012
BeijingWits Medical Limited
|
Jun. 30, 2013
BeijingWits Medical Limited
|
Feb. 15, 2012
BeijingWits Medical Limited
Maximum
|
Feb. 15, 2012
BeijingWits Medical Limited
Minimum
Employee
|
|
| Business Acquisition [Line Items] | |||||||||||||||
| Cash consideration | $ 78,661,000 | $ 51,563,000 | $ 51,897,000 | $ 37,199,000 | $ 9,000,000 | ||||||||||
| Additional consideration | 2,250,000 | 3,750,000 | 15,000,000 | 15,000,000 | 7,000,000 | 3,200,000 | 7,000,000 | ||||||||
| Reduction in contingent consideration | 1,500,000 | ||||||||||||||
| Additional consideration liability | 2,250,000 | 10,000,000 | |||||||||||||
| Amount held in escrow | 2,250,000 | ||||||||||||||
| Percentage of common stock acquired | 100.00% | 100.00% | |||||||||||||
| Further consideration paid in relation to certain performance milestones achieved | $ 5,000,000 | $ 3,800,000 | |||||||||||||
| Addition of new employees | 100 | ||||||||||||||
| X | ||||||||||
|
- Definition
Business Acquisition, Accrued Consideration Payable No definition available.
|
| X | ||||||||||
|
- Definition
Business Acquisition Cost Of Acquired Entity Amount Held In Escrow No definition available.
|
| X | ||||||||||
|
- Definition
Business Combination Contingent Consideration Arrangements Cash Payment Made No definition available.
|
| X | ||||||||||
|
- Definition
Number of Employees No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of Clinical Trial Services (Detail) (USD $)
In Thousands, unless otherwise specified |
6 Months Ended | 1 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Feb. 15, 2013
Clinical Trial Services
|
||||
| Business Acquisition [Line Items] | ||||||||
| Property, plant and equipment | $ 339 | |||||||
| Goodwill | 354,579 | 315,441 | 253,393 | 43,877 | [1] | |||
| Cash and cash equivalents | 1,039 | |||||||
| Accounts receivable | 9,185 | |||||||
| Unbilled revenue | 2,128 | |||||||
| Prepayments and other current assets | 414 | |||||||
| Other liabilities | (2,835) | |||||||
| Liability arising from contingent consideration arrangement | (2,250) | |||||||
| Net assets acquired | 51,897 | |||||||
| Cash consideration | 78,661 | 51,563 | 51,897 | |||||
| Contingent consideration | 2,250 | |||||||
| Amount of total consideration | 54,147 | |||||||
| Liabilities included in preliminary purchase price allocation re contingent consideration | (2,250) | |||||||
| Net assets acquired | $ 51,897 | |||||||
|
||||||||
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of PriceSpective LLC (Detail) (USD $)
In Thousands, unless otherwise specified |
6 Months Ended | 1 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Feb. 28, 2012
PriceSpective LLC
|
Feb. 28, 2012
PriceSpective LLC
Customer relationships acquired
|
Feb. 28, 2012
PriceSpective LLC
Order Backlog
|
Feb. 28, 2012
PriceSpective LLC
Non-compete Agreements
|
||||
| Business Acquisition [Line Items] | |||||||||||
| Property, plant and equipment | $ 256 | ||||||||||
| Goodwill | 354,579 | 315,441 | 253,393 | 42,247 | [1] | ||||||
| Intangible asset | 10,237 | 405 | 392 | ||||||||
| Cash and cash equivalents | 2,311 | ||||||||||
| Accounts receivable | 2,662 | ||||||||||
| Unbilled revenue | 1,140 | ||||||||||
| Other current assets | 236 | ||||||||||
| Current liabilities | (7,788) | ||||||||||
| Liability arising from contingent consideration arrangement | (15,000) | ||||||||||
| Net assets acquired | 37,098 | ||||||||||
| Cash consideration | 78,661 | 51,563 | 37,199 | ||||||||
| Working capital adjustment | (101) | ||||||||||
| Contingent consideration | 15,000 | ||||||||||
| Amount of total consideration | 52,098 | ||||||||||
| Liabilities included in preliminary purchase price allocation re contingent consideration | (15,000) | ||||||||||
| Net assets acquired | $ 37,098 | ||||||||||
|
|||||||||||
| X | ||||||||||
|
- Definition
Business Acquisition Purchase Price Allocation Working Capital No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of BeijingWits Medical Limited (Detail) (USD $)
In Thousands, unless otherwise specified |
6 Months Ended | 1 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Feb. 15, 2012
BeijingWits Medical Limited
|
Jun. 30, 2013
BeijingWits Medical Limited
|
Feb. 15, 2012
BeijingWits Medical Limited
Customer relationships acquired
|
Feb. 15, 2012
BeijingWits Medical Limited
Order Backlog
|
Feb. 15, 2012
BeijingWits Medical Limited
Non-compete Agreements
|
||||
| Business Acquisition [Line Items] | ||||||||||||
| Property, plant and equipment | $ 172 | |||||||||||
| Goodwill | 354,579 | 315,441 | 253,393 | 13,512 | [1] | |||||||
| Intangible asset | 1,761 | 376 | 97 | |||||||||
| Cash and cash equivalents | 587 | |||||||||||
| Accounts receivable | 657 | |||||||||||
| Unbilled revenue | 176 | |||||||||||
| Other current assets | 228 | |||||||||||
| Deferred tax liability | (559) | |||||||||||
| Current liabilities | (1,007) | |||||||||||
| Liability arising from contingent consideration arrangement | (7,000) | |||||||||||
| Net assets acquired | 9,000 | |||||||||||
| Cash consideration | 78,661 | 51,563 | 9,000 | |||||||||
| Contingent consideration | 7,000 | 3,200 | ||||||||||
| Amount of total consideration | 16,000 | |||||||||||
| Liabilities included in preliminary purchase price allocation re contingent consideration | (7,000) | (3,200) | ||||||||||
| Net assets acquired | $ 9,000 | |||||||||||
|
||||||||||||
| X | ||||||||||
|
- Definition
Business Acquisition, Purchase Price Allocation, Deferred Income Tax Liabilities No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Recognized Restructuring and Other Items, Net (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 6 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|---|
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Dec. 31, 2012
|
|
| Restructuring Cost and Reserve [Line Items] | |||||
| Restructuring charges | $ 4,621 | $ 4,525 | $ 9,033 | $ 4,525 | $ 4,500 |
| Other non-recurring items | 1,111 | 1,111 | |||
| Total | $ 4,621 | $ 5,636 | $ 9,033 | $ 5,636 | |
| X | ||||||||||
|
- Definition
Amount charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding asset retirement obligations net of research and development incentives. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
|
Restructuring and Other Items - Additional Information (Detail)
|
3 Months Ended | 6 Months Ended | 12 Months Ended | 3 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
USD ($)
|
Jun. 30, 2012
USD ($)
|
Jun. 30, 2013
USD ($)
|
Jun. 30, 2012
USD ($)
|
Jun. 30, 2012
EUR (€)
|
Dec. 31, 2012
USD ($)
|
Dec. 31, 2012
1st Quarter 2011 Restructuring Plan
USD ($)
|
Dec. 31, 2012
2012 Restructuring Plan
USD ($)
|
Mar. 31, 2013
1st Quarter 2013 Restructuring Plan
USD ($)
|
Jun. 30, 2013
1st Quarter 2013 Restructuring Plan
USD ($)
|
Jun. 30, 2013
2nd Quarter 2013 Restructuring Plan
USD ($)
|
Jun. 30, 2013
2nd Quarter 2013 Restructuring Plan
USD ($)
|
|
| Restructuring Cost and Reserve [Line Items] | ||||||||||||
| Restructuring charges | $ 4,621,000 | $ 4,525,000 | $ 9,033,000 | $ 4,525,000 | $ 4,500,000 | $ 100,000 | $ 4,400,000 | $ 4,412,000 | $ 4,600,000 | $ 4,621,000 | ||
| Lease termination and exit costs | 1,200,000 | 500,000 | ||||||||||
| Resource rationalizations | 1,111,000 | 1,111,000 | 3,400,000 | 3,900,000 | 4,200,000 | |||||||
| Lease termination and asset write down costs | 400,000 | |||||||||||
| Agreement settlement charges | 200,000 | 160,000 | ||||||||||
| Discretionary bonus | 243,000 | 243,000 | 194,000 | |||||||||
| Share-based compensation | $ 620,000 | |||||||||||
| X | ||||||||||
|
- Definition
Gain (Loss) On Contract Termination And Business Exit Costs No definition available.
|
| X | ||||||||||
|
- Definition
Lease Termination and Asset Write Down Costs No definition available.
|
| X | ||||||||||
|
- Definition
Restructuring, Settlement and Other Charges No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
|
Details of Movement in Restructuring Provisions Recognized (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 6 Months Ended | 12 Months Ended | 3 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | 6 Months Ended | 12 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Dec. 31, 2012
|
Mar. 31, 2013
1st Quarter 2013 Restructuring Plan
|
Jun. 30, 2013
1st Quarter 2013 Restructuring Plan
|
Jun. 30, 2013
2nd Quarter 2013 Restructuring Plan
|
Jun. 30, 2013
2nd Quarter 2013 Restructuring Plan
|
Jun. 30, 2013
Restructuring - Fiscal 2012 Plan
|
Dec. 31, 2012
Restructuring - Fiscal 2012 Plan
|
Jun. 30, 2013
Workforce Reduction
|
Jun. 30, 2013
Workforce Reduction
1st Quarter 2013 Restructuring Plan
|
Jun. 30, 2013
Workforce Reduction
2nd Quarter 2013 Restructuring Plan
|
Jun. 30, 2013
Workforce Reduction
Restructuring - Fiscal 2012 Plan
|
Dec. 31, 2012
Workforce Reduction
Restructuring - Fiscal 2012 Plan
|
Jun. 30, 2013
Office Consolidations
|
Jun. 30, 2013
Office Consolidations
1st Quarter 2013 Restructuring Plan
|
Jun. 30, 2013
Office Consolidations
2nd Quarter 2013 Restructuring Plan
|
Jun. 30, 2013
Office Consolidations
Restructuring - Fiscal 2012 Plan
|
Dec. 31, 2012
Office Consolidations
Restructuring - Fiscal 2012 Plan
|
|
| Restructuring Cost and Reserve [Line Items] | |||||||||||||||||||||
| Initial provision recognized | $ 4,621 | $ 4,525 | $ 9,033 | $ 4,525 | $ 4,500 | $ 4,400 | $ 4,412 | $ 4,600 | $ 4,621 | $ 4,644 | $ 8,131 | $ 3,903 | $ 4,228 | $ 3,394 | $ 902 | $ 509 | $ 393 | $ 1,250 | |||
| Cash payments | (4,369) | (623) | (3,854) | (4,280) | (197) | (3,030) | (89) | (426) | (824) | ||||||||||||
| Foreign exchange movement | (3) | (4) | (3) | (4) | |||||||||||||||||
| Provision balance at end of period | $ 4,661 | $ 4,661 | $ 163 | $ 786 | $ 3,848 | $ 163 | $ 360 | $ 813 | $ 426 | ||||||||||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Income Taxes Recognized During Period (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
|
| Reconciliation of Provision of Income Taxes [Line Items] | ||||
| Provision for income taxes before restructuring and other items | $ 4,315 | $ 3,514 | $ 9,336 | $ 6,240 |
| Tax impact of restructuring and other items | (595) | (705) | (1,850) | (705) |
| Provision for income taxes after restructuring and other items | $ 3,720 | $ 2,809 | $ 7,486 | $ 5,535 |
| X | ||||||||||
|
- Definition
Income Tax Expense (Benefit) Before Nonrecurring Charges No definition available.
|
| X | ||||||||||
|
- Definition
Income Tax Expense (Benefit) For Nonrecurring Charges, Net Of Tax No definition available.
|
| X | ||||||||||
|
- Definition
Income Tax Expense (Benefit) For Nonrecurring Charges, Tax No definition available.
|
| X | ||||||||||
|
- Details
|
|
Income Taxes - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified |
Jun. 30, 2013
|
Dec. 31, 2012
|
|---|---|---|
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | ||
| Liability for unrecognized tax benefit | $ 9.5 | $ 8.3 |
| Items generating unrecognized tax benefits | 8.1 | 7.2 |
| Interest and related penalties | $ 1.4 | $ 1.1 |
| X | ||||||||||
|
- Definition
Unrecognized Tax Benefits, Current Year Tax Positions No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Reconciliation of Number of Shares Used in Computation of Basic and Diluted Net Income Per Ordinary Share (Detail)
|
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
|
| Schedule of Weighted Average Number of Diluted Shares Outstanding [Line Items] | ||||
| Weighted average number of ordinary shares outstanding for basic net income per ordinary share | 60,724,296 | 59,978,509 | 60,555,945 | 60,032,306 |
| Effect of dilutive share options outstanding | 1,174,607 | 652,382 | 1,051,812 | 575,329 |
| Weighted average number of ordinary shares for diluted net income per ordinary share | 61,898,903 | 60,630,891 | 61,607,757 | 60,607,635 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Share-based Awards - Additional Information (Detail) (USD $)
|
6 Months Ended | 6 Months Ended | 6 Months Ended | 6 Months Ended | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
Employee Stock Plan, 2008 Plan
|
Jun. 30, 2013
Employee Stock Plan, 2008 Plan
Individual Employee
|
Jun. 30, 2013
Employee Stock Plan, 2008 Plan
Minimum
|
Jun. 30, 2013
Employee Stock Plan, 2003 Plan
|
Jun. 30, 2013
Employee Stock Plan, 2003 Plan
Individual Employee
|
Jul. 21, 2008
Restricted Stock Units 2008
|
Apr. 23, 2013
Restricted Stock Units And Performance Stock Units 2013
|
Jun. 30, 2013
Employee Stock Option
|
Jun. 30, 2012
Employee Stock Option
|
Jun. 30, 2013
Employee Stock Option
Minimum
|
Jun. 30, 2013
Employee Stock Option
Maximum
|
Jun. 30, 2013
Restricted Stock Units (RSUs)
|
Jun. 30, 2012
Restricted Stock Units (RSUs)
|
Jun. 30, 2013
Performance Share Unit (PSUs)
Minimum
|
Jun. 30, 2013
Performance Share Unit (PSUs)
Maximum
|
|
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||||||||||||||
| Percentage of option price for fair value of ordinary share | 100.00% | ||||||||||||||||
| Ordinary shares which have been reserved for issuance | 6,000,000 | 400,000 | 6,000,000 | 400,000 | 1,000,000 | 1,600,000 | |||||||||||
| Maximum number of award as percentage of shares outstanding | 10.00% | ||||||||||||||||
| Shares vesting period | 5 years | ||||||||||||||||
| Shares expiration period | 8 years | ||||||||||||||||
| Weighted Average Remaining Contractual Life of Options Outstanding | 4 years 6 months 18 days | 8 years | |||||||||||||||
| Options granted fair value | $ 3.68 | $ 13.93 | |||||||||||||||
| Weighted average fair value per option | $ 8.81 | ||||||||||||||||
| Exercisable - number of shares | 2,203,758 | ||||||||||||||||
| Exercisable - weighted average remaining contractual life | 3 years 3 months 26 days | ||||||||||||||||
| Exercisable - weighted average exercise price | $ 24.40 | ||||||||||||||||
| Fully vested total intrinsic value | 24,300,000 | ||||||||||||||||
| Intrinsic value of option exercised | 7,800,000 | 3,200,000 | |||||||||||||||
| Fair value of stock units vested | 1,100,000 | 0 | |||||||||||||||
| Number of shares expected to vest | 369,020 | ||||||||||||||||
| Cumulative EPS vesting period | 2013 | 2015 | |||||||||||||||
| Non-cash stock compensation expense not yet recognized | 43,000,000 | ||||||||||||||||
| Unrecognized stock-based compensation expense, weighted average period (years) | 2 years 10 months 24 days | ||||||||||||||||
| Tax benefit on exercise of options | $ 193,000 | $ 900,000 | |||||||||||||||
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Percentage of Fair Market Value No definition available.
|
| X | ||||||||||
|
- Definition
Share based Compensation Arrangement by Share based Payment Award, Options, Grants in Period, Fair Value No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Options, Grants in Period, Weighted Average Option Price No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award Other Than Options Expected Vesting Period No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Summary of Stock Option Activity (Detail) (Employee Stock Option, USD $)
|
3 Months Ended | 6 Months Ended | |
|---|---|---|---|
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
|
|
Employee Stock Option
|
|||
| Options Outstanding Number of Shares | |||
| Outstanding at beginning of period | 4,350,631 | ||
| Granted | 253,650 | ||
| Exercised | (524,243) | ||
| Forfeited | (273,401) | ||
| Outstanding at end of period | 3,806,637 | 3,806,637 | |
| Exercisable at end of period | 2,203,758 | 2,203,758 | |
| Weighted Average Exercise Price | |||
| Outstanding at beginning of period | $ 23.01 | ||
| Granted | $ 32.95 | ||
| Exercised | $ 20.11 | ||
| Forfeited | $ 25.47 | ||
| Outstanding at end of period | $ 23.89 | $ 23.89 | |
| Exercisable at end of period | $ 24.40 | $ 24.40 | |
| Weighted Average Fair Value | |||
| Outstanding at beginning of period | $ 9.17 | ||
| Granted | $ 12.06 | $ 9.72 | $ 12.05 |
| Exercised | $ 8.17 | ||
| Forfeited | $ 10.04 | ||
| Outstanding at end of period | $ 9.44 | $ 9.44 | |
| Exercisable at end of period | $ 8.86 | $ 8.86 | |
| Weighted Average Remaining Contractual Life | |||
| Outstanding at end of period | 4 years 6 months 18 days | ||
| Exercisable at end of period | 3 years 3 months 26 days | ||
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Forfeited in Period, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Options, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Summary of Movement in Non-Vested Share Options (Detail) (Employee Stock Option, USD $)
|
6 Months Ended |
|---|---|
|
Jun. 30, 2013
|
|
|
Employee Stock Option
|
|
| Number of Shares | |
| Beginning Balance | 2,094,533 |
| Granted | 253,650 |
| Vested | (578,193) |
| Forfeited | (167,111) |
| Ending Balance | 1,602,879 |
| Weighted Average Exercise Price | |
| Beginning balance | $ 22.43 |
| Granted | $ 32.95 |
| Vested | $ 24.83 |
| Forfeited | $ 22.91 |
| Ending balance | $ 23.18 |
| Weighted Average Fair Value | |
| Beginning Balance | $ 9.17 |
| Granted | $ 12.05 |
| Vested | $ 9.82 |
| Forfeited | $ 9.36 |
| Ending Balance | $ 9.36 |
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Forfeited in Period Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Granted in Period Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Granted in Period, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Definition
Share based Compensation Arrangement by Share based Payment Award, Nonvested Options, Grants in Period No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Outstanding, Number No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Outstanding Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Vested in Period No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Vested in Period Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Vested in Period, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
|
Schedule of Weighted Average Fair Values and Assumptions Used (Detail) (Employee Stock Option, USD $)
|
3 Months Ended | 6 Months Ended | |
|---|---|---|---|
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
|
|
Employee Stock Option
|
|||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
| Weighted average fair value | $ 12.06 | $ 9.72 | $ 12.05 |
| Assumptions: | |||
| Expected volatility | 41.00% | 50.00% | |
| Dividend yield | 0.00% | 0.00% | |
| Risk-free interest rate | 0.87% | 0.84% | |
| Expected life | 5 years | 5 years | |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Summary of RSU Activity (Detail) (Restricted Stock Units (RSUs), USD $)
|
6 Months Ended |
|---|---|
|
Jun. 30, 2013
|
|
|
Restricted Stock Units (RSUs)
|
|
| Options Outstanding Number of Shares | |
| Outstanding at beginning of period | 496,000 |
| Granted | 406,688 |
| Shares vested | (50,000) |
| Outstanding at ending of period | 852,688 |
| Forfeited | |
| Weighted Average Fair Value | |
| Outstanding at beginning of period | $ 20.26 |
| Granted | $ 34.42 |
| Shares vested | $ 22.30 |
| Forfeited | |
| Outstanding at end of period | $ 26.89 |
| Weighted Average Remaining Contractual Life | |
| Outstanding at end of period | 2 years 3 months |
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Cancelled and Forfeited in Period, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Unvested, Number No definition available.
|
| X | ||||||||||
|
- Definition
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Unvested, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Non-Cash Stock Compensation Expense (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
| Share-based compensation expense | $ 3,072 | $ 3,422 | $ 5,466 | $ 5,853 |
|
Direct costs
|
||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
| Share-based compensation expense | 1,693 | 1,544 | 3,012 | 2,883 |
|
Selling, General and Administrative Expense
|
||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
| Share-based compensation expense | 1,379 | 1,258 | 2,454 | 2,350 |
|
Restructuring And Other Charges
|
||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
| Share-based compensation expense | $ 620 | $ 620 | ||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
|
Distribution of Net Revenue by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 6 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
|||||||
| Segment Reporting Information [Line Items] | ||||||||||
| Net Revenue | $ 334,219 | $ 277,007 | $ 651,008 | $ 529,340 | ||||||
|
Ireland
|
||||||||||
| Segment Reporting Information [Line Items] | ||||||||||
| Net Revenue | 69,337 | [1] | 40,767 | [1] | 130,331 | [1] | 69,762 | [1] | ||
|
Rest Of Europe
|
||||||||||
| Segment Reporting Information [Line Items] | ||||||||||
| Net Revenue | 84,822 | 87,230 | 169,858 | 173,274 | ||||||
|
U.S.
|
||||||||||
| Segment Reporting Information [Line Items] | ||||||||||
| Net Revenue | 139,458 | 114,237 | 274,933 | 221,984 | ||||||
|
Rest of World
|
||||||||||
| Segment Reporting Information [Line Items] | ||||||||||
| Net Revenue | $ 40,602 | $ 34,773 | $ 75,886 | $ 64,320 | ||||||
|
||||||||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
|
Distribution of Income from Operations, including Restructuring and Other Items, by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
|
| Segment Reporting Information [Line Items] | ||||
| Income from operations | $ 26,299 | $ 11,004 | $ 49,295 | $ 22,736 |
|
Ireland
|
||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations | 12,827 | (305) | 24,843 | (6,601) |
|
Rest Of Europe
|
||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations | 3,531 | 6,701 | 7,317 | 16,422 |
|
U.S.
|
||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations | 7,740 | 1,712 | 13,277 | 8,269 |
|
Rest of World
|
||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations | $ 2,201 | $ 2,896 | $ 3,858 | $ 4,646 |
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
|
Distribution of Income from Operations, excluding Restructuring and Other Items, by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
|
| Segment Reporting Information [Line Items] | ||||
| Income from operations, excluding Restructuring and other items | $ 30,920 | $ 16,640 | $ 58,328 | $ 28,372 |
|
Ireland
|
||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations, excluding Restructuring and other items | 13,556 | 1,770 | 25,897 | (4,526) |
|
Rest Of Europe
|
||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations, excluding Restructuring and other items | 5,198 | 7,247 | 10,755 | 16,968 |
|
U.S.
|
||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations, excluding Restructuring and other items | 9,579 | 4,362 | 17,369 | 10,919 |
|
Rest of World
|
||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations, excluding Restructuring and other items | $ 2,587 | $ 3,261 | $ 4,307 | $ 5,011 |
| X | ||||||||||
|
- Definition
Operating Income Loss Before Restructuring Charges No definition available.
|
| X | ||||||||||
|
- Details
|
|
Distribution of Property, Plant and Equipment, Net, by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
Jun. 30, 2013
|
Dec. 31, 2012
|
|---|---|---|
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | $ 162,280 | $ 168,373 |
|
Ireland
|
||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | 104,645 | 110,369 |
|
Rest Of Europe
|
||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | 15,032 | 16,115 |
|
U.S.
|
||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | 34,441 | 32,400 |
|
Rest of World
|
||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | $ 8,162 | $ 9,489 |
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|
|
Distribution of Depreciation and Amortization by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
|
| Segment Reporting Disclosure [Line Items] | ||||
| Depreciation and amortization | $ 11,520 | $ 10,830 | $ 22,976 | $ 21,632 |
|
Ireland
|
||||
| Segment Reporting Disclosure [Line Items] | ||||
| Depreciation and amortization | 4,836 | 4,506 | 9,825 | 9,001 |
|
Rest Of Europe
|
||||
| Segment Reporting Disclosure [Line Items] | ||||
| Depreciation and amortization | 1,688 | 1,759 | 3,422 | 3,739 |
|
U.S.
|
||||
| Segment Reporting Disclosure [Line Items] | ||||
| Depreciation and amortization | 3,987 | 3,535 | 7,705 | 6,937 |
|
Rest of World
|
||||
| Segment Reporting Disclosure [Line Items] | ||||
| Depreciation and amortization | $ 1,009 | $ 1,030 | $ 2,024 | $ 1,955 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Distribution of Total Assets by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
Jun. 30, 2013
|
Dec. 31, 2012
|
|---|---|---|
| Segment Reporting Information [Line Items] | ||
| Assets | $ 1,293,122 | $ 1,202,108 |
|
Ireland
|
||
| Segment Reporting Information [Line Items] | ||
| Assets | 508,504 | 476,159 |
|
Rest Of Europe
|
||
| Segment Reporting Information [Line Items] | ||
| Assets | 237,348 | 236,305 |
|
U.S.
|
||
| Segment Reporting Information [Line Items] | ||
| Assets | 496,922 | 437,756 |
|
Rest of World
|
||
| Segment Reporting Information [Line Items] | ||
| Assets | $ 50,348 | $ 51,888 |
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Details
|